GlassScriptPhysician profile
Antoine L Samaha
NPI 1639113624
$4,124.15
in general payments reported to CMS, 2019-2025
33 companies · $920 in 2025
The $920 reported for 2025 was more than what 76% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $979 · 2021: $231 · 2022: $135 · 2023: $433 · 2024: $1,103 · 2025: $920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,366 · Education: $90.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,365.80 |
| Education | $90.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $673.86 | 2023-2025 | Jardiance |
| Merit Medical Systems INC | $663.31 | 2020 | |
| W. L. Gore & Associates, INC. | $315.92 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $313.43 | 2019-2025 | Farxiga |
| Calliditas Therapeutics US INC. | $292.25 | 2022-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $274.82 | 2023-2025 | |
| Bard Peripheral Vascular, INC. | $197.10 | 2020-2023 | Pristine |
| Argon Medical Devices, INC. | $174.77 | 2024 | Clot Management |
| Amgen INC. | $154.36 | 2019-2025 | Krystexxa, Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $128.71 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $106.86 | 2024-2025 | Jynarque, Voyxact |
| Horizon Therapeutics Plc | $92.86 | 2022-2023 | Krystexxa |
| Amarin Pharma, INC. | $89.38 | 2023 | |
| Ardelyx, INC. | $71.48 | 2024 | Ibsrela |
| Opko Pharmaceuticals, LLC | $67.90 | 2024-2025 | Rayaldee |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $66.15 | 2020 | |
| Alexion Pharmaceuticals, INC. | $65.68 | 2024 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $62.96 | 2024-2025 | |
| Vifor Pharma, INC. | $38.79 | 2022-2023 | Veltassa, Korsuva |
| Mallinckrodt Hospital Products INC. | $28.83 | 2025 | Terlivaz |
| Alnylam Pharmaceuticals INC. | $27.79 | 2021 | |
| Baxter Healthcare | $26.98 | 2019 | |
| Outset Medical INC | $25.20 | 2023 | |
| Glaxosmithkline, LLC. | $24.75 | 2023 | Benlysta |
| Fresenius USA Marketing, INC. | $22.22 | 2024 | |
| Genzyme Corporation | $16.36 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.31 | 2024 | Gattex |
| Kyowa Kirin, INC. | $15.38 | 2025 | |
| Scpharmaceuticals INC. | $14.53 | 2025 | |
| Cook Medical LLC | $14.12 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $13.82 | 2024 | Crysvita |
| Covidien LP | $13.75 | 2019 | |
| Venturemed Group, INC. | $13.52 | 2025 | Flex Vessel Prep System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antoine Samaha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.